Loading
Sacituzumab tirumotecan / Patritumab deruxtecan / Cetuximab · Phase 1/2 Trial
ClinicalTrials.gov · August 6, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a planned Phase 1/2 trial of MK-1084, a targeted therapy, combined with monoclonal antibodies and antibody–drug conjugates in patients with advanced or metastatic non-squamous non-small cell lung cancer. The registry record describes intended enrollment and primary endpoints (dose-limiting toxicity, adverse events, objective response rate) but contains no efficacy or safety results; clinical meaningfulness cannot yet be assessed.
Phase 1/2, Interventional, Randomized, Sequential, Open label, Treatment purpose. Lung Neoplasm Malignant; age from 18 Years. Intervention: MK-1084 + Patritumab deruxtecan (HER3-DXd); MK-1084 + Sacituzumab tirumotecan (Sac-TMT); MK-1084 + Cetuximab. n = 140. 27 sites across 11 countries.
This is a planned Phase 1/2 trial of MK-1084, a targeted therapy, combined with monoclonal antibodies and antibody–drug conjugates in patients with advanced or metastatic non-squamous non-small cell lung cancer. The registry record describes intended enrollment and primary endpoints (dose-limiting toxicity, adverse events, objective response rate) but contains no efficacy or safety results; clinical meaningfulness cannot yet be assessed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
This is an active Phase 1/2 trial registration with no results posted; it describes planned enrollment and safety/efficacy endpoints but reports no outcome data.
As stated by the source record.
Quoted from the source exactly as published.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07286149). This is a study registration, not published results. Lead sponsor: Merck Sharp & Dohme LLC. Recruitment status: RECRUITING. Phase: PHASE1, PHASE2. Study type: INTERVENTIONAL. Enrollment: 140 participants (ESTIMATED). Conditions: Lung Neoplasm Malignant. Interventions: DRUG: MK-1084; BIOLOGICAL: Patritumab deruxtecan; BIOLOGICAL: Sacituzumab tirumotecan; BIOLOGICAL: Cetuximab; DRUG: Rescue Medications. Primary outcome measures: Number of Participants Who Experience a Dose Limiting Toxicity (DLT) , Up to 42 days; Number of Participants Who Experience an Adverse Event (AE) , Up to approximately 63 months; Number of Participants Who Discontinue Study Treatment Due to an AE , Up to approximately 62 months; Objective Response Rate (ORR) , Up to approximately 63 months. Brief summary: Researchers want to learn if MK-1084, the study medicine, can treat advanced or metastatic non-squamous NSCLC. MK-1084 is a targeted therapy, which is a treatment that works to control how specific types of cancer cells grow and spread. The goals of this study are to learn: * About the safety of MK-1084 and if people tolerate it when taken with other treatments * How many people have the cancer respond (get smaller or go away) to the treatments
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.